公开(公告)号：US20230256017A1

公开(公告)日：2023-08-17

申请号：US17801669

申请日：2021-02-26

申请人： Jennifer BROGDON ,  Glenn DRANOFF ,  Michael R. GREENE ,  Anniesha HACK ,  Olja KODRASI ,  Elizabeth Dorothy PRATICO ,  Andrew PRICE ,  Andrew Marc STEIN ,  Amy RAYO ,  Jennifer YANG ,  Brian Walter GRANDA ,  Novartis AG

发明人： Jennifer BROGDON ,  Glenn DRANOFF ,  Michael R. GREENE ,  Anniesha HACK ,  Olja KODRASI ,  Elizabeth Dorothy PRATICO ,  Andrew PRICE ,  Andrew Marc STEIN ,  Amy RAYO ,  Jennifer YANG ,  Brian Walter GRANDA ,  Attilio BONDANZA ,  Boris ENGELS ,  Hyungwook LIM ,  Akash SOHONI ,  Louise TREANOR ,  Xu ZHU ,  Carla GUIMARAES ,  Shyamali JAYASHANKAR ,  Sandeep Tharian KOSHY ,  Regis CEBE ,  Michael BARDROFF ,  Sandra MILLER

IPC分类号： A61K35/17 ,  A61P35/00

CPC分类号： A61K35/17 ,  A61P35/00

摘要： The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods.

公开(公告)号：US20230037682A1

公开(公告)日：2023-02-09

申请号：US17311315

申请日：2019-12-04

申请人： NOVARTIS AG

发明人： Brian Walter GRANDA ,  Daniel LENHERR-FREY ,  Xuerui LUO ,  Amy RAYO ,  Fei ZHANG ,  Jiquan ZHANG

IPC分类号： C07K16/28

摘要： Provided are CD3 binding molecules that specifically bind to CD3, for example monospecific binding molecules that specifically bind to CD3 and multispecific binding molecules (MBMs) that specifically bind to CD3 and a tumor-associated antigen, conjugates comprising the CD3 binding molecules, and pharmaceutical compositions comprising the CD3 binding molecules and conjugates. Provided are methods of using the CD3 binding molecules, conjugates, and pharmaceutical compositions to activate T cells in a subject, for example a subject having a cancer or autoimmune disease. Provided are recombinant host cells engineered to express the CD3 binding molecules and methods of producing the CD3 binding molecules by culturing the host cells under conditions in which the CD3 binding molecules are expressed.

公开(公告)号：US20240025993A1

公开(公告)日：2024-01-25

申请号：US18035470

申请日：2021-11-04

申请人： NOVARTIS AG

发明人： Regis CEBE ,  Dattananda CHELUR ,  Brian Walter GRANDA ,  Connie WONG ,  Sunyoung JANG ,  Haihui LU ,  Amy RAYO ,  Darko SKEGRO

IPC分类号： C07K16/28 ,  A61P35/00

CPC分类号： C07K16/2803 ,  A61P35/00 ,  C07K2317/565 ,  C07K2317/52 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/622 ,  C07K2317/55

摘要： The present disclosure provides CD19 binding molecules that specifically bind to CD19, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.

公开(公告)号：US20240002509A1

公开(公告)日：2024-01-04

申请号：US18251913

申请日：2021-11-04

申请人： Novartis AG

发明人： Brian Walter GRANDA ,  Darko SKEGRO

IPC分类号： C07K16/28 ,  C12N15/63

CPC分类号： C07K16/2809 ,  C12N15/63 ,  C07K2317/24 ,  C07K2317/71 ,  C07K2317/31 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/524

摘要： The present invention relates to antibodies comprising Fc variants and their uses. The Fc variants exhibit reduced or undetectable binding to Fc receptors, and reduced or undetectable effector functions. These variants are beneficial for a patient suffering from a disease which could be treated with an antibody for which it is desirable to reduce the effector functions induced by antibodies.